Welcome to our dedicated page for BLI news (Ticker: bli), a resource for investors and traders seeking the latest updates and insights on BLI stock.
Berkeley Lights, Inc. (BLI) delivers breakthrough solutions in single-cell analysis and biotechnology innovation. This news hub provides investors and industry professionals with essential updates on the company's scientific advancements, strategic partnerships, and operational developments.
Access official press releases covering BLI's OptoSelect™ technology enhancements, financial results, and collaborations with leading biopharma organizations. Our curated collection helps stakeholders track progress in cell therapy development, diagnostic innovations, and research platform expansions.
Discover updates on regulatory milestones, intellectual property achievements, and technology applications in drug discovery. The repository serves as a critical resource for understanding BLI's role in advancing precision medicine and life science research tools.
Bookmark this page for direct access to verified company announcements. Check regularly for insights into how Berkeley Lights continues to shape the future of biotechnology through cutting-edge single-cell manipulation solutions.
On November 18, 2020, Berkeley Lights announced a public offering of 3,000,000 shares of common stock at $86.00 per share, sold by certain stockholders. An additional 450,000 shares may be purchased by underwriters within 30 days. The offering is set to close around November 23, 2020, pending customary conditions. All net proceeds will go to the selling stockholders, while Berkeley Lights will receive no funds. J.P. Morgan, Morgan Stanley, and Cowen are the lead managers for this offering.
Berkeley Lights, a leader in Digital Cell Biology, is launching a public offering of 3,000,000 shares of common stock by certain selling stockholders, with an additional 450,000 shares available through a 30-day underwriter option. The selling stockholders will receive all net proceeds, while Berkeley Lights will not benefit from this offering. J.P. Morgan, Morgan Stanley, and Cowen are the lead managers for this offering. A registration statement has been filed with the SEC but is not yet effective. This announcement does not constitute an offer to sell securities.
Berkeley Lights, Inc. (BLI) reported Q3 2020 financial results with total revenue of $18.2 million, a 16% increase year-over-year. Product revenue reached $14.1 million (up 7%), while service revenue surged 66% to $4.1 million. Gross profit rose to $12.8 million, with a gross margin of 70%. However, operating expenses increased by 32% to $21 million, leading to a net loss of $8.6 million, compared to $4.4 million in Q3 2019. Cash reserves totaled $237.2 million as of September 30, 2020.
Berkeley Lights, Inc. (Nasdaq: BLI) will announce its third-quarter 2020 financial results on November 12, 2020, after market close. A conference call with management will follow at 1:30 p.m. PT / 4:30 p.m. ET, accessible via the company's website. Berkeley Lights focuses on Digital Cell Biology, offering a platform for rapid development of biotherapeutics by capturing extensive data on single cells. The platform aims to standardize processes in the cell-based product value chain.
Mycenax Biotech has adopted the Berkeley Lights Platform for cell line development, marking a significant advancement in Taiwan's biopharmaceutical landscape. The Beacon system will enhance Mycenax's efficiency, allowing for a reduction in cell line development timelines by up to 50%. This strategic partnership aims to produce high-quality cell lines for complex antibody therapeutics, ensuring unparalleled clonality assurance in under one week. With this integration, Mycenax reinforces its commitment to high standards in biologics development, amid the rapid growth of the biopharmaceutical sector in Asia Pacific.
Berkeley Lights, a leader in Digital Cell Biology, will participate in the Morgan Stanley Virtual Healthcare Conference on September 15, 2020, at 8:00 a.m. Pacific Time. The management team will engage in a fireside chat, which can be accessed via a live and archived webcast on their website. Berkeley Lights focuses on accelerating biotherapeutics development through its innovative platform, which captures critical data from single cells. Their technology aims to set industry standards in cell-based product development.
Berkeley Lights, Inc. (BLI) reported a total revenue of $10.6 million for Q2 2020, a 10% decline year-over-year. Product revenue increased by 17% to $9.1 million, while service revenue fell by 63% to $1.5 million. The company's gross profit decreased to $7.0 million, with a gross margin drop to 66% from 81%. Operating expenses rose 26% to $19.1 million, resulting in a net loss of $12.4 million, compared to $6.2 million in Q2 2019. Berkeley Lights recently completed an IPO, raising approximately $188 million.
Berkeley Lights has successfully closed its initial public offering of 9,315,000 shares of common stock, raising approximately $204.9 million at a price of $22.00 per share. This includes the full exercise of an option for an additional 1,215,000 shares by underwriters. Trading of its common stock commenced on the Nasdaq under the ticker symbol BLI on July 17, 2020. The offering was managed by J.P. Morgan, Morgan Stanley, and Cowen, with a registration statement declared effective by the SEC on July 16, 2020.
Berkeley Lights has priced its initial public offering at $22.00 per share, offering 8,100,000 shares, with a potential additional 1,215,000 shares available to underwriters. The gross proceeds are expected to be approximately $178.2 million. Trading on the Nasdaq under the ticker symbol BLI is set to commence on July 17, 2020, with the offering closing on July 21, 2020. J.P. Morgan, Morgan Stanley, and Cowen are the lead managers for this offering.
